Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma

E. Montefusco, F. Fazi, I. Cordone, C. Ariola, M. Nanni, A. Spadea, M. A. Aloe Spiriti, S. Fenu, F. Mandelli, M. C. Petti

Research output: Contribution to journalArticlepeer-review

Abstract

The occurrence of acute myeloid leukemia (AML) as a secondary tumor has been frequently reported in patients who received various chemotherapy regimens for hematologic malignancies while the concomitant development of chronic lymphoproliferative diseases (CLD) and AML in previously untreated patients is extremely rare. We report a case with an apparently spontaneous occurrence of AML and non Hodgkin low-grade lymphoma diagnosed by immunological, cytogenetical and molecular analyses. In particular genetic studies allowed to identify the coexistence of a clonal lymphoid population and a myeloid blast component characterized by inv(16) marker and CBFbeta-MYH11 gene fusion. Complete remission of AML and the CLD was obtained following high doses of hydroxyurea and two consolidation cycles of fludarabine plus intermediate dose cytarabine.

Original languageEnglish
Pages (from-to)671-674
Number of pages4
JournalLeukemia and Lymphoma
Volume40
Issue number5-6
Publication statusPublished - 2001

Keywords

  • AML
  • Chronic lymphoproliferative disease
  • Fludarabine and cytarabine
  • HU high-doses
  • Inv (16)high - dose hydroxyurea

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Molecular remission following high-dose hydroxyurea and fludarabine plus cytarabine in a patient with simultaneous acute myeloid leukemia and low-grade lymphoma'. Together they form a unique fingerprint.

Cite this